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Background: The use of bone marrow concentrate (BMC) for treatment of musculoskeletal
disorders has become increasingly popular over the last several years, as technology has improved
along with the need for better solutions for these pathologies. The use of cellular tissue raises a
number of issues regarding the US Food and Drug Administration’s (FDA) regulation in classifying
these treatments as a drug versus just autologous tissue transplantation. In the case of BMC in
musculoskeletal and spine care, this determination will likely hinge on whether BMC is homologous
to the musculoskeletal system and spine.
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Objectives: The aim of this review is to describe the current regulatory guidelines set in place by
the FDA, specifically the terminology around “minimal manipulation” and “homologous use” within
Regulation 21 CFR Part 1271, and specifically how this applies to the use of BMC in interventional
musculoskeletal medicine.
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Methods: The methodology utilized here is similar to the methodology utilized in preparation of
multiple guidelines employing the experience of a panel of experts from various medical specialties
and subspecialties from differing regions of the world. The collaborators who developed these
position statements have submitted their appropriate disclosures of conflicts of interest. Trustworthy
standards were employed in the creation of these position statements. The literature pertaining to
BMC, its effectiveness, adverse consequences, FDA regulations, criteria for meeting the standards of
minimal manipulation, and homologous use were comprehensively reviewed using a best evidence
synthesis of the available and relevant literature.
Results/Summary of Evidence: In conjunction with evidence-based medicine principles, the
following position statements were developed:
Statement 1: Based on a review of the literature in discussing the preparation of BMC using
accepted methodologies, there is strong evidence of minimal manipulation in its preparation, and
moderate evidence for homologous utility for various musculoskeletal and spinal conditions qualifies
for the same surgical exemption.
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Statement 2: Assessment of clinical effectiveness based on extensive literature shows emerging evidence for multiple
musculoskeletal and spinal conditions.

•	The evidence is highest for knee osteoarthritis with level II evidence based on relevant systematic reviews, randomized controlled trials and nonrandomized studies. There is level III evidence for knee cartilage conditions.
•	Based on the relevant systematic reviews, randomized trials, and nonrandomized studies, the evidence for disc
injections is level III.
•	Based on the available literature without appropriate systematic reviews or randomized controlled trials, the
evidence for all other conditions is level IV or limited for BMC injections.
Statement 3: Based on an extensive review of the literature, there is strong evidence for the safety of BMC when performed by
trained physicians with the appropriate precautions under image guidance utilizing a sterile technique.
Statement 4: Musculoskeletal disorders and spinal disorders with related disability for economic and human toll, despite
advancements with a wide array of treatment modalities.
Statement 5: The 21st Century Cures Act was enacted in December 2016 with provisions to accelerate the development and
translation of promising new therapies into clinical evaluation and use.
Statement 6: Development of cell-based therapies is rapidly proliferating in a number of disease areas, including musculoskeletal
disorders and spine. With mixed results, these therapies are greatly outpacing the evidence. The reckless publicity with unsubstantiated
claims of beneficial outcomes having putative potential, and has led the FDA Federal Trade Commission (FTC) to issue multiple
warnings. Thus the US FDA is considering the appropriateness of using various therapies, including BMC, for homologous use.
Statement 7: Since the 1980’s and the description of mesenchymal stem cells by Caplan et al, (now called medicinal signaling
cells), the use of BMC in musculoskeletal and spinal disorders has been increasing in the management of pain and promoting
tissue healing.
Statement 8: The Public Health Service Act (PHSA) of the FDA requires minimal manipulation under same surgical procedure
exemption. Homologous use of BMC in musculoskeletal and spinal disorders is provided by preclinical and clinical evidence.
Statement 9: If the FDA does not accept BMC as homologous, then it will require an Investigational New Drug (IND) classification
with FDA (351) cellular drug approval for use.
Statement 10: This literature review and these position statements establish compliance with the FDA’s intent and corroborates
its present description of BMC as homologous with same surgical exemption, and exempt from IND, for use of BMC for treatment
of musculoskeletal tissues, such as cartilage, bones, ligaments, muscles, tendons, and spinal discs.
Conclusions: Based on the review of all available and pertinent literature, multiple position statements have been developed
showing that BMC in musculoskeletal disorders meets the criteria of minimal manipulation and homologous use.
Key words: Cell-based therapies, bone marrow concentrate, mesenchymal stem cells, medicinal signaling cells, Food and Drug
Administration, human cells, tissues, and cellular tissue-based products, Public Health Service Act (PHSA), minimal manipulation,
homologous use, same surgical procedure exemption
Pain Physician 2020: 23:E85-E131

M

usculoskeletal disorders represent a major
cause of morbidity and result in enormous
costs for health and social care systems (111). Chronic and inflammatory diseases of joints and the
spine, including osteoarthritis, and low back pain caused
by intervertebral disc degeneration with involvement
of the 3-joint complex, are major causes of disability in
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young and elderly alike (12). The disability and cost of
health care continue to increase despite the number of
available treatment modalities and significant increases
in health care expenditures (3-49). Consequently, a shift
in health care strategies has been advocated involving
novel pharmacologic and biological therapies that can
effectively treat these disorders.
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Development of cell-based therapies is being rapidly incorporated into treatment plans for a number of
disease processes, including musculoskeletal disorders
and spine. The results are mixed. The use of cell-based
therapy is greatly outpacing the evidence (12,49-71).
The public awareness that biologics have regenerative potential has been acknowledged by their highly
publicized use in professional athletes, and because of
the national debate on embryonic stem cells (49,72).
Consequently, the result of this irresponsible publicity
with unsubstantiated claims of miraculous outcomes
(57) has led the Federal Trade Commission (FTC) to take
action against stem cell therapy clinics found to be in
violation of the truth in advertising law (58). In addition, misrepresentation of uncharacterized, minimally
manipulated, allogenic cell preparation as “stem cells,”
or the use of more than minimally manipulated cell
preparations, have led to a widespread clinical use of
unproven biologic therapies (49,73,74). The US Food
and Drug Administration (FDA) has had no recourse
but to investigate multiple stem cell clinics and publish
new guidance (59-74). Physicians using bone marrowderived medicinal signaling cells or mesenchymal stem
cells (BM-MSC) therapy must elucidate, justify, and recommend that the FDA consider bone marrow concentrate (BMC) as “homologous use.” The sheer volume of
unsubstantiated claims and lack of high-level research
has led to a health Canada policy position paper on the
use of autologous cell therapy products (75). In addition, concerns over misinformation and inappropriate
application of stem cell therapy have led to recent calls
to action from professional organizations including the
National Academy of Sciences (NAS), the International
Society for Cellular Therapy (ISCT), the American Association for the Advancement of Science (AAAS), the
American Academy Orthopedic Surgeons (AAOS), and
American Society of Interventional Pain Physicians
(ASIPP) (3,49,50,76-78). Each of these groups recognize
the potential value of cell therapies and the risk that
the current environment may erode the public trust.
Responsible investments are needed to bring legitimate
cellular and biological therapies to patients (49).
Regenerative medicine continues to develop based
on the scientific principles of evidence-based medicine
with its effectiveness shown in multiple musculoskeletal
disorders and in managing spinal pain (3,49,50,78-112).
In contrast to traditional medical therapies, stem cellbased therapies integrate tissue-engineering technologies and biomaterial science fundamental to the science
of regenerative medicine. Thus, tissue engineering
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approaches for cartilage and intervertebral disc repair
will benefit from advances in MSCs based repair strategies (106).
The 21st Century Cures Act was enacted in December 2016, with provisions to accelerate the development and translation of promising new therapies into
clinical evaluation and use (52,113). This bipartisan and
bicameral legislation increased funding for medical
research, and for combatting the opioid epidemic, including measures to streamline approval of new therapies for clinical trials (49,52). The 21st Century Cures
Act also provided a new expedited biologics product
development program called Regenerative Medicine
Advanced Therapy (RMAT) (63). The key elements of
RMAT include accelerated FDA approval for regenerative medicine therapy that is intended to treat a condition and shows a potential to address unmet clinical
needs for some diseases or conditions, such as chronic
musculoskeletal and spine conditions.
In regenerative medicine the present focus of
cell therapy has been on 2 types of stem cells, namely
bone marrow-derived stem cells and adipose-derived
stem cells. However, with the FDA regulations on stem
cell therapy, adipose-derived cell therapies have been
considered as a drug. Thus BMC is currently the only
viable strategy left in the United States covered under
the 21 CFR 1271.15 (b) same surgical exemption despite
many emerging autologous cell therapy products. Unfortunately, some countries, including Canada, have
regulated all types of stem cells, essentially restricting
cell therapy in their countries (75).
Bone marrow is the organ responsible for the
generation of blood and immune cells, with mesenchymal cells supporting hematopoiesis (107,108,114).
Bone marrow transplants begin in the 1960s and beginning in the 1980s, BMC began to be used in musculoskeletal pathologies. Based on the therapeutic
properties of the cells and growth factors contained
in the bone marrow, its use has been tested in several
types of disease entities and injuries with positive outcomes, including musculoskeletal disorders and spinal
disorders (108,114-118). Historically, Till and McCulloch (117) in 1963 demonstrated that bone marrow
transplantation (BMT) was able to reconstitute the
hematopoietic system of mice that had their system
completely depleted by irradiation. In 1966, Friedenstein et al (115) showed that bone marrow contained
a distinct type of cell capable of forming bone tissue when cultured in diffusion chambers and then
implanted in mice. These cells were later described
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as mesenchymal cells (116). Since then, in the 1980s,
Arnold Caplan and colleagues published their work
on the isolation of MSCs from BMC and the ability of
these cells to differentiate into bone and cartilage in
specific in vitro conditions (107,119-122). Caplan (120)
also renamed mesenchymal stem cells as medicinal
signaling cells with the acronym remaining the same–
MSCs. Since Caplan, there has been rapid expansion
of the basic and clinical literature investigating the
potential therapeutic application of stem cell therapy
and regenerative medicines (3,49,50,79-108). In vitro
studies showed that (BM-MSCs can be purified, culture
expanded, and induced to differentiate into mesodermal tissue types (57,123-125). Investigations into potential clinical applications for musculoskeletal injury
and disease (including spinal disorders), range from
a variety of soft issue biologic treatment modalities,
including direct soft tissue and osseous injections, as
well as intravascular therapy to intraarticular therapy,
and intradiscal therapy, all of which have increased
exponentially (50). Despite the development of a
clinical and therapeutic basis for use of BM-MSCs and
other forms of stem cell therapy, clinical applications
have far outpaced the basic and transitional science
required to confirm their potential effectiveness and
safety (3,46,50-71,107,126-134).
The Public Health Service Act (PHSA) defines the
laws surrounding the control of the spread of communicable diseases in organ or tissue transplants.
The FDA has since created regulations found in 21
CRR 1271 based on the PHSA, which control the use
of human cells, tissues, and cellular and tissue-based
products (HCT/Ps), including both autologous and
allogenic bone marrow-derived tissue preparations
(52,61,62,135). Two broad categories of tissue preparations intended to be injected or infused into human
recipients are described in 21 CFR 1271 applying to
HCT/Ps that are minimally manipulated and intended
for homologous use (135) or those that are more than
minimally manipulated or intended not to be used in
a homologous way. The FDA described that the processing procedure for minimally manipulated cells or
tissues must not “alter the original relevant characteristics relevant to the tissues’ utility for reconstructive,
repair, and replacement,” and must not “alter relevant
biological characteristics of cells or tissue.” Further,
the FDA defines homologous use as, “the repair, reconstruction, replacement, or supplementation of the
recipient’s cells or tissues with an HCT/P that performs
the same basic function or functions in the recipient as
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in the donor” (135). In addition to these 2 important
aspects of the regulation, 21 CFR 1271 also requires
that the cells are not combined with any other tissue
or product except for “water, crystalloids, or a sterilizing, preserving, or storage agent.” Thus cell and tissue
preparations that meet the criteria described in 1271
can be administered to patients without obtaining
premarket clearance or an investigational new drug
(IND) classification from the FDA.
In addition, if the HCT/Ps have passed a minimal
manipulation test as described earlier, then they are
eligible to be exempt under 21 CFR 1271.15(b). This
same surgical procedure exemption contemplates that
the cells are extracted and reintroduced into the same
patient (autologous) during the same surgical procedure (135).
Based on the FDA regulation and present concepts,
autologous BMC meets the definitions of minimal manipulation without controversy. In addition, it meets
the definition of the 21 CFR 1271.15(b) same surgical
procedure exemption as well. However, the second aspect of the definition, which is homologous use when
used to treat musculoskeletal applications, has still yet
to be decided. This issue has evolved into not only a
subject of discussion, but also of concern based on the
Canadian position on autologous cell therapy products
(75). A Health Canada Policy position paper with the
regulatory frameworks under the Food and Drug Act
provided oversight of safety, efficacy, and quality, while
enabling patient access to potentially promising new
therapies in 2019, declared that autologous cell therapy
products meeting the definition of “drug” in persons
who prepare or manufacture and administer or distribute must comply with Sections 8 and 11 of the Food
and Drug Act (75,136,137). This Health Canada policy
change now includes BMC in the “drug” category.
However, Health Canada continues to work to identify
and overcome challenges specific to meeting regulatory requirements for the manufacturing and sale of
autologous cell therapy products.
Other international regulatory authorities, such
as the European Medicine Agency, have laws similar to
Canada’s that allow them to regulate the distribution
of cell therapy products in their respective jurisdictions.
However, the European Union has enacted regulations
specifically for cell therapy products, whereas US FDA
and Health Canada applied existing drug regulatory
frameworks. In addition, some regulatory authorities
have special exemptions for cell therapy products, including those that are prepared at the bedside during
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the “same surgical procedure” or “hospital exemptions” where all of the tissue processing with administration occurs within the same establishment.
In reviewing US FDA guidance documents, the
way in which the FDA ultimately addresses this issue will depend on classification of bone marrow as
“homologous” or “nonhomologous.” Fulfillment of
this criteria for autologous BMC that is used as part of
same surgical procedure exemptionis required for this
procedure to be regulated by the state medical boards
and not the FDA. If BMC does not meet all of these criteria it will fall outside of the same surgical procedure
exemption and require an IND classification with FDA
approval for use. Therefore to be FDA compliant and
exempt from an IND, the use of BMC for treatment
of musculoskeletal tissues, such as cartilage, bone,
ligaments, muscle, tendons, and spinal discs, must be
considered homologous.
This position paper provides a comprehensive, focused review of bone marrow MSC therapy. This policy
position paper describes the current regulatory guidelines set in place by the FDA, specifically the terminology around “homologous use” with specific application
to BMC.
ASIPP has been at the forefront of guideline development for the use of interventional techniques,
opioids, and biologics in the management of low back
pain, antithrombotics in interventional techniques, and
the use of sedation (3,4,138-140). The present position
statement has been developed to describe the role of
BM-MSCs therapy in musculoskeletal disorders, with
a comprehensive review of the literature of BM-MSC
therapy. This position statement includes an overview
of the current literature applicable to BMC and MSC applications in the musculoskeletal system, including the
spine. This position statement specifically incorporates
the various aspects of FDA guidance and provides a basis for asserting that BMC meets the criteria for minimal
manipulation, same surgical procedure exemption, and
homologous use.

Methods
Rationale
The National Uniform Claims Committee (NUCC)
defines interventional pain management as the discipline of medicine devoted to the diagnosis and treatment of pain-related disorders, principally with the
application of interventional techniques in managing
subacute, chronic, persistent, and intractable pain,
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independently or in conjunction with other modalities
of treatment (141). In addition, the Medicare Payment
Advisory Commission (MedPAC) defines interventional
pain management techniques as “minimally invasive
procedures including percutaneous precision needle
placement of drugs in targeted areas or ablation of
targeted nerves; surgical techniques such as laser and
endoscopic discectomy; and the placement of intrathecal infusion pumps and spinal cord stimulators for the
diagnosis and management of chronic, persistent, or
intractable pain” (142).
Chronic musculoskeletal and spinal pain are complex and multifactorial disease processes. The high
prevalence of chronic musculoskeletal and spinal pain,
the numerous treatment modalities applied in the management of the problem, and the growing social and
economic costs continue to influence medical decisionmaking. Interventional pain physicians are familiar with
various image-guided interventional techniques for the
management of spinal pain and musculoskeletal pain.
The technical skills and training required for the various
delivery methods of BMC fall well within interventional
pain managements purview.

Objectives
This position paper provides a comprehensive, focused review of bone marrow MSC therapy. This policy
position paper describes the current regulatory guidelines set in place by the FDA, specifically the terminology around “homologous use” with specific application
to BMC.

Adherence to Trustworthy Standards
In preparation of this position statement for BMC,
the standards from the Institute of Medicine (IOM) and
the National Guideline Clearinghouse Extent Adherence to Trustworthy Standards (NEATS) were followed
(143-145). The NEATS instrument was developed and
tested as a tool to be used with strict adherence by the
trained staff at the Agency for Healthcare Research and
Quality (AHRQ) in providing an assessment focused on
NEATS.

Disclosure of Funding Source for Position
Statement
The evidence-based policy position statement on
BMC therapy in musculoskeletal and spinal disorders
were commissioned, prepared, edited, and endorsed
by ASIPP without seeking or obtaining any external
funding.
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Disclosure and Management of Financial Conflicts
of Interest
Potential conflicts of interest for all panel members
within the last 5 years were evaluated prior to the finalizing of these guidelines. Conflicts of interests extended beyond financial relationships, including personal
experiences, practice patterns, academic interests, and
promotions. Participants with previously established
conflicts are considered those with opinions not being
in line with the previously developed ASIPP guidelines
or the overall philosophical approach of ASIPP. The
panel members with potential conflicts were recused
from discussion or preparation of the guidelines in
which they had conflicts of interest, and these members
agreed not to discuss any aspect of a given guideline
with the related industry before data publication.

Composition of Position Development Group
A panel of experts in BMC from various medical
fields, convened by ASIPP, reviewed the evidence and
formulated recommendations for BMC therapy as it applies to musculoskeletal and spinal disorders. The panel
constituted a broad representation of academic and
non-academic clinical practitioners with an interest and
expertise in the application of BMC in musculoskeletal
and spinal disorders.

evidence synthesis developed by Cochrane Review, and
have incorporated multiple guidelines modified by
ASIPP, as shown in Table 1 (146).

Grading or Rating the Quality or Strength of
Evidence
An evidence-based position statement has both
similarities and differences when compared with practice guidelines. For the development of this position
statement, the evidence is based on literature review
and consensus. The traditional instruments for the
grading of evidence based on randomized controlled
trials, observational studies, and other clinical reports,
with a major focus on systematic reviews and metaanalysis may not be utilized, to the same extent as in
the preparation of guidelines (3,4,138,140). However,
the grading of evidence based on ASIPP guidelines,
founded on the quality of evidence and the strength of
recommendations as proposed by AHRQ (144,145), as
shown in Table 2, were utilized.

Assessment and Recommendations of Benefits
and Harms
This position statement clearly
the
potential
beneficial
evidence
recommendations.

describes
summary

Evidence Review

Evidence Summary of Recommendations

This position statement was developed with consensus among the panel members after review of the
published literature concerning the use and safety of
BMC therapy in musculoskeletal and spinal disorders
with chronic noncancer pain.
The recommendations for this position statement
have been developed using the principles of best

This position statement summarizes the relevant
supporting evidence.

Specificity of the Statement
This position statement is specific and unambiguous, providing guidance on BMC therapy in musculoskeletal and spinal disorders.

Table 1. Qualitative modified approach to grading of evidence.

Level I

Strong

Evidence obtained from multiple relevant high-quality randomized controlled trials for
effectiveness.

Level II

Moderate

Evidence obtained from at least one relevant high-quality randomized controlled trial or
multiple relevant moderate or low-quality randomized controlled trials.

Level III

Fair

Evidence obtained from at least one relevant high-quality nonrandomized trial or observational
study with multiple moderate- or low-quality observational studies.

Level IV

Limited

Evidence obtained from multiple moderate- or low-quality relevant observational studies.

Level V

Consensus based

Opinion or consensus of large group of clinicians and/or scientists for effectiveness as well as to
assess preventive measures, adverse consequences, effectiveness of other measures.

Adapted from Manchikanti L, Falco FJE, Benyamin RM, Kaye AD, Boswell MV, Hirsch JA. A modified approach to grading of evidence. Pain Physician 2014; 17:E319-E325 (146).
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Table 2. Guide for strength of recommendations.

Rating for Strength of Recommendation
There is high confidence that the recommendation reflects best practice. This is based on: a) strong evidence for a true
net effect (e.g., benefits exceed harms); b) consistent results, with no or minor exceptions; c) minor or no concerns
about study quality; and/or d) the extent the panelists’ agreement. Other compelling considerations (discussed in the
guideline’s literature review and analyses) may also warrant a strong recommendation.

Strong

Moderate

There is moderate confidence that the recommendation reflects best practice. This is based on: a) good evidence for
a true net effect (e.g., benefits exceed harms); b) consistent results, with minor and/or few exceptions; c) minor and/
or few concerns about study quality; and/or d) the extent of panelists’ agreement. Other compelling considerations
(discussed in the guideline’s literature review and analyses) may also warrant a moderate recommendation.
There is some confidence that the recommendation offers the best current guidance for practice. This is based on: a)
limited evidence for a true net effect (e.g., benefits exceed harms); b) consistent results, but with important exceptions;
c) concerns about study quality; and/or d) the extent of panelists’ agreement. Other considerations (discussed in the
guideline’s literature review and analyses) may also warrant a weak recommendation.

Weak

Source: National Guideline Clearinghouse Extent Adherence to Trustworthy Standards (NEATS) instrument (144).

External Review
This position statement has been subjected to external peer review as per the policies of the publishing
journal, Pain Physician.

Updating the Position Statement
BMC therapy in musculoskeletal disorders will be
updated within 5 years or less, based on significant
changes in the scientific evidence, public policy, or adverse events occurring on or before March 2025.

Impact

of

Musculoskeletal Disorders

Health Care and Disability
Health care expenditures have been escalating
over the years. Recent estimates of the US health care
spending reached $3.66 trillion in 2018 (147). In addition, expenditures will continue to grow each year with
estimates showing that national health expenditures
will grow at an average annual growth rate of 5.5%
from 2018 to 2027 (148). Simply put, the 2018 cost
of $3.65 trillion in spending represents $11,212 per
person, but keeping all variables stable, that cost per
person in 2027 will rise to $12,197.04. US spending
on personal and public health care from 1996 to 2013
(1), showed an estimated spending of $87.6 billion in
managing low back and neck pain, and $95.5 billion
in managing musculoskeletal disorders, with a total
spending on musculoskeletal disorders and spinal pain
of approximately $183 billion.
The impact of chronic pain is enormous (1,2,49,12,138,147-155). The annual US expenditures alone
(including direct medical costs and lost wages) may
be higher than those for cancer, heart disease, and
diabetes combined (1,2,5). Despite high expenditures
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and numerous treatment option, disability continues to
escalate. Figure 1 shows expenditures related to musculoskeletal conditions, including back and neck pain,
as determined in 2016 based on US spending on health
care (1).
Musculoskeletal conditions are the leading contributors to disability in the United States and worldwide.
In addition to musculoskeletal pain contributing to
disability, it has also been associated with a number of
conditions in older people, such as low physical activity,
poor mobility, frailty, depression, cognitive impairment,
and poor sleep quality (155).
A study of the state of the US health between 1990
and 2010, describing the burden of diseases, injuries,
and risk factors (6), showed that with increasing life
expectancy, morbidity, and chronic disability accounted
for nearly half of the US health burden, despite substantial progress and improvement in health. Among the 30
leading diseases and injuries contributing to years lived
with disability in the United States between 1990 and
2010, low back pain, other musculoskeletal disorders,
and neck pain ranked numbers 1, 3, and 4, respectively
(6). More recent analysis of the state of US health from
1990 to 2016 (7) showed similar results with low back
pain, other musculoskeletal disorders, and neck pain
ranking numbers 1, 4, and 6, respectively. Similar to low
back pain, other musculoskeletal disorders (specifically
osteoarthritis) caused substantial pain and disability
impacting the quality of life. Hip and knee osteoarthritis has been ranked at the 11th highest contributor to
global disability, and 38th highest in years lived with
disability (156).
Chronic persistent spinal pain lasting longer
than 1 year is reported in 25% to 60% of patients
(3,8,138,157). Similarly, the prevalence of knee and hip
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Fig. 1. Estimated health care spending by aggregated age group, type of payer, and aggregated health category in 2016.
Reported in 2016 US dollars. Each of the 3 columns sums to the estimated $2.7 trillion of 2016 spending disaggregated in this study. The width
of each line reflects the relative share of the estimated $2.7 trillion attributed to that age group, type of payer, or aggregated health category.
a
Includes maternal, neonatal, and nutritional disorders.
With permission: Dieleman JL, Cao J, Chapin A, et al. US health care spending by payer and health condition, 1996-2016. JAMA 2020;
323:863-884 (2).

osteoarthritis is over 25% in individuals over the age
of 45 (158). Although the literature shows that over
27 million adults in the United States age 25 years and
older have a clinical diagnosis of osteoarthritis of any
joint, 5.6 million cases of these present with lower
extremity osteoarthritis (159-163). It is also estimated
that 13 million adults age 60 years and older in the
United States have radiographic osteoarthritis, with approximately 4 million of those individuals classified as
having symptomatic knee osteoarthritis (162). Further,
individuals sustaining a knee injury are 4.2 times more
likely to develop osteoarthritis than those without a
history of knee injury (164). In addition to osteoarthritis
of hip and knee, shoulder osteoarthritis is ranked as the
third most common cause of osteoarthritis. A multitude
of other osteoarthritis conditions occur commonly after
trauma (162).
Of the estimated spending of $264.3 billion as
annual expenditures for musculoskeletal disorders,
including spinal disorders, as shown by Dieleman et al
(1,2), $134.6 billion was spent in managing low back
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and neck pain, an increase from $87.6 billion in 2013, a
44.4% increase from $183.5 billion from 2013 to 2016
for musculoskeletal disorders and spinal disorders. A
multitude of other assessments have also shown significant health care spending and its impact for musculoskeletal disorders. An IOM study (5) showed the cost
of chronic pain to range from $560 to $635 billion per
year, which includes spinal pain, chronic pain, and other
painful conditions (Table 3) (5,150,165). The literature
has been explicit in showing unsustainable increases
in all types of therapies starting with over-the-counter
drug therapy, alternative modalities to prescription
drugs, conservative management, minimally invasive
procedures, and surgical interventions (3,4,10-49).
Thus, the impact of musculoskeletal disorders on
health care is enormous with substantial human toll
leading to a multitude of issues, the most important
being disability with reduced quality of life.

Opioid Epidemic
Opioid use has become a major issue in the United

www.painphysicianjournal.com

BMC Therapy in Musculoskeletal Disorders: Position Statement of ASIPP

States, with its escalating use, treatment costs, and
preventative measures used in effort to control the explosion of the opioid epidemic (4,13,16,23,25,166-181).
The US drug overdosage data of drug-related deaths
from 2017 shows escalating statistics with over 70,000
drug overdoses, of which 47,600 were related to opioid
overdoses, as shown in Fig. 2 (177). It has been shown
that the majority of the increases are related to synthetic opioids, as well as heroin. The recent data shows
a 14.5% drop in prescription drug opioid deaths to less
than 12,000. However, heroin deaths continue to increase, and in 2017 there were over 15,000 deaths due
to heroin, as shown in Fig. 3. Fentanyl deaths are the
category largely responsible for the escalating opioid
epidemic (178).
Sixty-three percent of deaths involve various other
drugs in addition to prescription opioids with 34%
cocaine, 33% benzodiazepines, and 12% methamphetamines (179). Even though deaths due to prescription
opioids are declining, the overall opioid deaths continue
to increase. Further, the age-old comparison of increasing prescriptions correlating with increasing deaths has
been nullified now that prescriptions are declining (Fig.
4). In fact, opioid prescription data in the United States
shows a significant decline from 251.8 million prescriptions in 2013 to 168.8 million prescriptions in 2018, as
shown in Fig. 5 (181).
Even though there is overwhelming evidence
that the epidemic of opioid use involves not only the
use of prescription opioids, but fentanyl and heroin,

Table 3. The prevalence and cost of chronic pain.
♦The annual cost of chronic pain is $560 to $635 billion a year
• Direct cost due to pain is $261 – $300 billion
♦Prevalence estimates
• 10% moderate pain
• 11% severe pain		
Total 21%
• 33% joint pain
• 25% arthritis
•12% functional disability
♦Moderate pain $4,516
♦Severe pain $3,210
♦Joint pain $4,048
♦Arthritis $5,838
♦Functional disability $9,680
Source: Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain 2012; 13:715-724 (149).

policy experts appear to have focused on prescription
opioids as the main target in the United States (16).
Manchikanti et al (16) described various issues related
to the opioid epidemic and pointed out the tragic failure of current systems to control opioid misuse. It was
this misuse that propagated the epidemic, starting
with the pain movement together with a confluence
of interest and failure of oversight from the opioid industry, which was largely responsible for the epidemic.
Multiple issues related to the confluence of interest included promotion of opioids based on inadequate evidence with advocacy from Portenoy and Foley (182).
Subsequently, the Fifth Vital Sign was established in
1995, which became a universal phenomenon (16).
Further, fuel was added by guidelines implemented

Fig. 2. National drug overdose
deaths—number among all
ages, 1999 to 2017.
Source: Centers for Disease
Control and Prevention, National
Center for Health Statistics.
Multiple Cause of Death 19992017 on CDC WONDER Online
Database, released December,
2018 (177).
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Fig. 3. Quantification of
opioid deaths.

Source: https://www.drugabuse.gov/related-topics/
trends-statistics/overdosedeath-rates (178).

Fig. 4. Opioid prescriptions at 10-year low and overdose deaths at 10-year high.
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Fig. 5. Total opioid
prescriptions in the
United States in
millions.

Source: https://
www.end-opioidepidemic.org/
wp-content/
uploads/2019/06/
AMA-Opioid-TaskForce-2019-ProgressReport-web.pdf.

by the medical boards. These guidelines were written
theoretically for appropriate opioid usage, but were
essentially being developed by the opioid industry.
There were also failures in oversight of not only opioid
manufacturing, distribution, diversion, and import,
but also in medical necessity and appropriate monitoring of opioid prescriptions (16).
The significant movement to control the opioid
epidemic in the United States was initiated with prescription drug monitoring programs, state regulations,
curbing opioid productions, and increasing the focus on
education. Overall federal spending increasing by 128%
from 2017 to 2018 with the major increases in federal
spending due to treatment and recovery programs with
costs ranging from approximately $599 million to $2.1
billion (183-195). Total opioid spending increased from
$3.3 billion in 2017 to $7.4 billion in 2018 in the United
States (183). The numerous regulations and enhanced
prescription drug monitoring programs have also contributed to the decreases in opioid prescriptions from
a high of 255 million in 2012 to 191 million in 2017, a
decrease of 25%.
Overall the decline in the number of prescriptions
with reduced dosages, faces a multitude of criticisms
against the Centers for Disease Control and Prevention
(CDC) guidelines and other measures (193-198). Consequently, US Department of Health & Human Services,
as well as the CDC, have clarified and are encouraging
providing opioids for patients with appropriate medi-
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cal necessity, even though they continue to focus on
reduced utilization (197,198).

BMC
Bone marrow is a semi-solid tissue found within
spongy or cancellous portions of bones. The cellular
components of bone marrow include osteoblasts, osteoclasts, macrophages, endothelial progenitor cells
(EPCs), hematopoietic stem cells (HSCs), and MSCs
(108,199). BMC, also known as bone marrow aspirate
concentrate (BMAC), is created by centrifuging bone
marrow aspirate. This process results in 3 layers with the
plasma in the supernatant, the buffy coat in the middle,
and the red blood cell layer in the infranatant (108).
To create BMC, the buffy coat is isolated. Contained
in this layer is a number of cells, including MSCs, HSCs,
myelopoietic and erythropoietic cells, mature leukocytes, platelets, and megakaryocytes (108). Among the
cellular components, MSCs are largely credited with the
therapeutic potential of BMC to treat musculoskeletal
pathology due to their ability to self-replicate and differentiate into other cell types such as osteoblasts and
chondrocytes (200).
The use of bone marrow in medicine can be traced
back to the 1940s and 1950s when the first discoveries
of irradiating and protecting mice with a BMT were
performed (201). Studies followed showing leukemic
mice could be treated by infusion of normal mouse
bone marrow (201-203). Early human studies infusing
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allogeneic marrow were ineffective at establishing a
graft other than in identical twins (201-203). The first
successful graft treatment in a human patient with
leukemia was published in 1965 (204,205). By the late
1960s, increasing knowledge of human histocompatibility antigen systems made successful BMT possible
(201). By the 1970s, BMT became more commonly used
in refractory cases of leukemia (205). In the late 1980s,
Caplan and colleagues published their work on the
isolation of the MSCs from the bone marrow and the
ability of MSCs to differentiate into bone and cartilage
in vitro (107,119-122).
There has been significant discussion in reference
to the effectiveness of BMC and in the nomenclature,
as well as the inconsistencies (206). The ISCT in 2016
defined specific criteria that must be met for cells to
be considered MSCs. The criteria included that the cells
must be plastic-adherent in standard culture conditions,
must display specific surface antigens, and must show
in vitro differentiation into osteoblasts, adipocytes, and
chondroblasts (207). As the understanding continues to
evolve, MSCs have been defined as mesenchymal stem
cell, mesodermal stem cell, and mesenchymal stromal
cell, often simultaneously by different groups that continue to disagree on the most accurate name for the cell
type (120). In addition, based on the ability to undergo
in vitro osteogenesis and costochondral genesis (206208), MSCs were initially thought to maintain their multipotency after injection into an injured joint. Thus the
term “mesenchymal stem cell” was used to describe the
hypothesized ability to differentiate and regenerate injured cartilage or soft tissue (107). However, subsequent
evidence has demonstrated that MSCs are rather derived
from pericytes or perivascular cells surrounding capillary
endothelium (120-122,209). Further, studies also have
suggested that injected MSCs do not undergo differentiation in vivo and the primary functionality is not that of
a stem cell (210,211). Despite the hypothesis that MSCs
are no longer thought to exhibit stem-like properties in
vivo, they have been shown to induce endogenous stem
cell activity and secrete bioactive factors that promote
tissue healing (122,212-217). Consequently, the perivascular source and immunomodulary effects of the BMC
make both “stem cell” and “stromal cell” inaccurate
descriptions of MSCs. This has led to a modification of
the meaning of MSC being changed from “mesenchymal
stem cell” to “medicinal signaling cell” to emphasize
their role as trophic mediators by Caplan (120).
Charbord (206) in a review provided the historical
emergence of the concept of bone marrow MSCs, sum-
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marizing the data on hematopoietic inductive microenvironment (218), hematopoiesis supportive stromal
cells (219), osteogenic cells (220), trilineal osteoblastic,
chondrocytic, and adipocytic precursors (124,220), to
finally introduce the specific bone marrow MSCs with
differentiation potential, and stromal and immunomodulatory capacities. Charbord (206) described 2
points in detail. The first point envisioned the stem cell
attributes as having multipotentiality, self-renewal, tissue regeneration, population heterogeneity, plasticity,
and lineage priming, compared with the attributes of
paradigmatic HSCs. In the second point, believing the
possible existence of bone marrow cells with even larger differentiation potential, eventually pluripotential
cells were discussed. This review led to the conclusion
that bone marrow MSCs can constitute a specific adult
tissue stem cell population. The multiple characteristics
of this stem cell type accounts for the versatility of the
mechanisms of injured tissue repair.
In a consensus statement, Chu et al (49) describe
the characteristics of stem cells and minimally manipulated autologous cell preparations with BMC, as shown
in Table 4 (221).
Since the discovery of MSCs, BMC has been used
extensively to treat musculoskeletal diseases since the
1980s (222). The first case series on the use of BMC to
treat nonunion fracture and avascular necrosis was
published by Hernigou et al (223) in the mid-2000s. In
the last decade, many physicians have started utilizing
BMC to address common musculoskeletal conditions,
such as osteoarthritis and tendon injuries. The body of
literature to support this use is growing and at present includes multiple randomized controlled trials
(49,80,81,87-112,224-248).

US FDA Regulatory Context
The FDA uses the term “human cells, tissues or
tissue-based products” (or “HCT/Ps”) when describing
human cells or tissues that are “intended for implantation, transplantation, infusion or transfer into a human
recipient.” The FDA’s regulation of HCT/Ps involves a
tiered risk structure and a multipart test (135).
The “tiered, risk-based approach” to the regulation of HCT/Ps was first announced by the FDA in 1997,
and was finalized in regulations found at 21 CFR Part
1271 in 2005. The 21 CFR Part 1271.10 includes an
important criteria through which all HCT/Ps must be
vetted to determine whether any specific HCT/P will
be subject to the FDA’s IND and Biologics License Application requirements, or will merely qualify for the
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Table 4. Characteristics of MSCs and minimally manipulated cell preparations of BMC.

Cell Type

Definition

MSCs

Three minimum characteristics:
1. Capable of division and self-renewal for long periods of time
2. Unspecialized
3. Can give rise to specialized cell types

BMC, minimally manipulated autologous cell
preparations

Cleared for homologous use
Processing must not alter the relevant biological characteristics of cells or tissues
Mixed cell populations, with variable composition
Stem or progenitor cells may be present at lower prevalence
Biological attributes and function highly variable

Adapted from: Chu CR, Rodeo S, Bhutani N, et al. Optimizing clinical use of biologics in orthopaedic surgery: Consensus recommendations from
the 2018 AAOS/NIH U-13 Conference. J Am Acad Orthop Surg 2019; 27:e50-e63 (49).

Part 1271 regulations themselves (135). In the present
context (physician use in offices or operating rooms),
these regulations create a binary regulatory pathway in
which one category is regulated only by the Part 1271
regulations themselves, whereas the other is regulated
as a drug requiring the full gamut of the FDA drug approval process.
Autologous HCT/Ps that are either “more than
minimally manipulated” or used for a “nonhomologous” purpose are deemed by the FDA to present more
risk and cannot be used in the United States without
the FDA’s permission in the form of an approved IND or
biologic license application. Alternatively, autologous
HCT/Ps that are “minimally manipulated” and used for
homologous purposes may either be regulated as a tissue product, subject to FDA’s registration, listing, in Part
1271 requirements, or as surgical procedures, which
would fall into FDA’s “same surgical procedure” exemption found at 21 CFR 1271.15 and regulated primarily
at the state level. Finally, bone marrow is exempt from
regulation as an HCT/P if it is minimally manipulated
and used for a homologous purpose; 21 CFR 1271.3(d)
(135). Hence throughout this analysis, the HCT/Ps that
are minimally manipulated and also used for a homologous purpose fall within critical distinctions that govern
how the HCT/P is regulated.
Given the minimal processing involved in the creation of BMC, it fits under the FDA’s minimal manipulation definition. Indeed, using a parallel example involving a blood product, the FDA wrote in its guidance
that when a “manufacturer performs cell selection…to
obtain a higher concentration of hematopoietic stem/
progenitor cells (HPCs) for transplantation…[t]he HCT/P
would generally be considered minimally manipulated
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because the concentrated peripheral blood stem/progenitor cells are not altered with regard to their relevant biological characteristic” (249).
However, the second part of the regulatory classification, homologous use, is now open to interpretation.
This paper will address this last remaining question,
that is what constitutes the “homologous use” of autologous bone marrow? Homologous use is defined
as “the repair, reconstruction, replacement, or supplementation of a recipient’s cells or tissues with an HCT/P
that performs the same basic function or functions in
the recipient as in the donor” 21 CFR Part 1271.3(c).
However, with respect to bone marrow, to date the
FDA has only provided the following guidance:
First, in a subsequently withdrawn Guidance Document published in 2016, the FDA wrote as follows: “The
basic functions of hematopoietic stem/progenitor cells
(HPCs) include to form and to replenish the hematopoietic system. Sources of HPCs include cord blood,
peripheral blood, and bone marrow.” Thus as of 2016,
if a procedure involved the use of HPCs to address a
disorder affecting the hematopoietic system, the procedure would have been considered to be a homologous
use of the HPCs (250).
Second, in its finalized Guidance dated November
2017, the FDA wrote as follows: “Sources of hematopoietic stem/progenitor cells (HPCs) include cord blood,
peripheral blood, and bone marrow. The basic functions of HPCs include forming and replenishing the
lymphohematopoietic system” (249). Thus as of today,
if a procedure involves the use of HPCs to address a disorder affecting the lymphohematopoietic system, the
procedure will be considered the homologous use of
the HPCs.
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Hence what the existing medical literature states
about how the body uses bone marrow to maintain or
heal musculoskeletal and spinal disorders will have a
profound effect on the regulation of BMC in musculoskeletal medicine. In other words, if BMC is homologous
to common musculoskeletal tissues and disc, then it is
left unregulated by the FDA, but if nonhomologous,
then it can be classified as a drug, and is subject to the
FDA’s drug approval requirement (135).

Impact

of

Bone Marrow Cells

on

Healing

As shown in the literature, the historical emergence
of the concept of bone marrow mesenchymal cells is
complex with a number of clinical applications ranging
from musculoskeletal to neurologic indications, but
more specifically musculoskeletal disorders as described
herewith.

Bone
Bone has the ability to self-repair largely because
the cells responsible for initiation and completion of
the repair reside within the bone marrow. Many of
these bone marrow cells are capable of osteogenesis
and vasculogenesis (251). This osteogenic potential has
prompted many physicians through the decades to use
bone grafts or bone marrow to help heal delayed-union
and nonunion fractures (252). The components in bone
marrow that help bone naturally heal are those present
in BMC.
Bone marrow is a multifunctional mixture of anucleate red blood cells and platelets, as well as nucleated
cells that include multipotent stem cells and progenitor cells (253). The nucleated cells within this mixture
have hematopoietic, angiogenic, and osteogenic potential (254). The 3 primary multipotent cell types that
populate bone marrow are HSCs, MSCs, and EPCs. Bone
marrow’s essential functions include hematopoiesis,
osteogenesis, and vasculogenesis (255).
When a fracture occurs, the liquid portion of the
bone marrow flows into the space created. The cellular
content of this liquid is believed to drive the fracture
repair (251). The osteogenic potential of bone marrow
was first discovered in BM-MSCs in the 1960s (256,257),
with later work illuminating MSCs’ ability to differentiate into osteoblasts and osteocytes depending on
local environmental cues (125,258). It has been shown
in vitro and in vivo that a single HSC can also have
hematopoietic or osteogenic potential depending on
environmental factors and the surrounding conditions
(259).
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Vasculogenesis is another essential function of
bone marrow cells (260). Bone healing has been shown
to occur via mobilization of EPCs from bone marrow,
which encourage vasculogenesis in the setting of structural damage and ischemia (254,260-262). Bone marrow
cells require transportation via this newly established
vasculature to initiate the healing cascade, induce
callus formation, and instigate bone remodeling and
healing (253). Evidence suggests special populations
of EPCs in specific bone marrow niches are available
for rapid release in response to ischemic conditions, as
well as matrix metalloproteinases (MMPs). This environment induces tubulization and new vessel formation to
restore adequate oxygen delivery and allow for bony
remodeling (262-264).
Surgeons have long used the ability of bone to heal
fractures by utilizing the natural elements found in
structural bone and bone marrow. For example, autologous and allogeneic bone grafts have been commonly
used for more than a century to heal nonunion fracture
(252). In the 1990s, Hernigou et al (222,264) again published on the use of autologous BMC to heal nonunion
fracture in addition to its application in the treatment
of avascular necrosis.
BMC contains multipotent cells capable of osteogenesis, as well as growth factors, cytokines, and
chemokines active in osteopoiesis (265-267). It has been
shown that an intraosseous injection of BMC can help
heal nonunion fracture by replenishing the native and
healthy cellular composition of the normal bone (126).
Hence injecting BMC into the bone is performed, in
part, to reestablish osteogenic potential with newly engrafted cells that can serve to replace and/or enhance
native cell functionality (199).

Cartilage
Cartilage is an avascular tissue made up of chondrocytes and extracellular matrix (ECM) that consists
of water, collagen, and proteoglycans (251). It derives
its nutrition and ability for self-repair largely by its
communication with the underlying bone marrow
through the subchondral plate. This natural relationship between bone and cartilage has been utilized by
surgeons to help heal cartilage lesions using bone marrow stimulation techniques since the late 1980s to early
1990s (268,269).
Articular cartilage is produced during bone development when chondrocytes are replaced by osteoblasts
in the long bone during the endochondral ossification
process (270). It is important in the overall health of
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diarthrodial joints and serves to protect the joint by reducing friction between surfaces and absorbing impact
(251). It is primarily composed of an ECM and chondrocytes (251). Varying ratios of collagen fibers, ECM,
and chondrocytes contribute to the superficial, middle,
deep, and calcified zones of cartilage (271). Cartilage
has several known healing mechanisms. The cellular response involves progenitor cells at the cartilage surface,
as well as MSCs recruited from the synovial fluid and
membrane (272). In addition, there is another cellular
response that can occur from beneath the cartilage,
which is mediated through the bone marrow (273).
More recently, the connection between the cartilage
health, local microenvironment, and the interaction
with cell-based therapies have been explored (270).
Injury to cartilage can naturally expose the subchondral bone marrow, which contains various cellular
components, such as MSCs and a variety of growth
factors that assist in healing and repair (273-275). One
of the most important functions of MSCs is directing
chondrogenesis through paracrine activity, which reduces cell apoptosis and inflammation, while activating cell proliferation and mobilization (276). For an
isolated cartilage lesion to heal in which there has been
no subchondral plate exposure, there must be natural
communication between the cartilage and bone marrow through channels in the subchondral plate (268).
The formation of sclerosis and calcification of cartilage
in osteoarthritis can interfere with this communication,
as can an increase in fatty marrow (277). However, in
acute trauma to the cartilage with a normal subchondral plate, blood flow via healthy subchondral fenestrae is drastically increased in the cancellous bone to
assist in the healing process. Madry et al (199) demonstrated that MSCs from the nearby subchondral bone
are subsequently mobilized, migrate to form a clot, and
differentiate into chondrocytes/osteoblasts, which over
time form repair tissue to fill the defect.
In addition to cellular components, cartilage
repair also involves growth factors such as fibroblast
growth factor (FGF), vascular endothelial growth factor
(VEGF), insulin growth factor-1 (IGF-1), and transforming growth factor beta, which all play different roles
and are able to stimulate chondrocyte differentiation
of MSCs, increase chondrocyte proliferation, as well
as decrease the catabolic effects of cytokines, such as
interleukin-1 (IL-1) and MMPs (278).
Undifferentiated bone marrow MSCs can be seen
at the chondral lesion by day 7 post injury and a cartilaginous matrix at day 10 (199). At 6 weeks, the chon-
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dral lesion is fully populated with fibrocartilaginous
cells and chondrocytes (199). Any traumatic injuries to
the subchondral plate are reestablished by 24 weeks
when the majority of cartilage healing has taken place,
replacing cancellous bone with the lamellar bone (199).
Surgeons have developed surgical techniques
utilizing bone marrow as a natural reservoir of cartilage healing cells for decades. The microfracture and
microdrilling techniques used to treat cartilage lesions
create holes in the subchondral plate to release adjacent bone marrow, which initiates a healing response
in osteochondral injury (268,269). These procedures
have been shown to cause fibrocartilaginous healing
that can provide a return to normal function in select
patients (279). However, the cartilage produced is type
I cartilage and not the original type II hyaline cartilage.
As such it is more friable. BMC therapy has been shown
to produce type II cartilage.

Ligament
Both intrinsic and extrinsic cellular mechanisms
play a role in ligament healing. Evidence regarding the
relationship of ligament healing to bone marrow can
be found in dental models involving the periodontal
ligament (PDL) (280). BM-MSCs have been shown to
mobilize the injured knee’s anterior cruciate ligament
(ACL) (281). In addition, the health of the underlying
bone and the knee ACL ligament appear to be interrelated (281). Similarly, surgeons have made use of this
relationship by performing microfracture at the ACL
origin or insertion to liberate BM-MSCs to enhance ligament healing (282).
Ligaments are fibrous bands that attach bone to
bone. The area where the ligament makes that connection is known as the enthesis. The cellular components of
ligaments include fibroblasts, collagen, elastin, proteoglycans, glycolipids, and fibronectin, with fibroblasts being the predominant cell type and collagen fibrils a key
structural feature (283). These fibrils are predominantly
comprised of type I collagen and to a lesser extent type
III collagen. Although considered relatively hypovascular,
there are blood vessels found in close proximity to the
fibrils, with penetrating vascular channels that provide
nutrition (284). Ligamentous injury involves structural
disruption of these penetrating vessels, in addition
to the ECM. Cellular insult occurs, and similar to other
tissues, a healing response comprised of inflammation,
proliferation, and remodeling follows (249).
Disrupted blood vessels result in localized bleeding
and hematoma formation. The immediate response is
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one of vasoconstriction of the injured vessels and the
initiation of the coagulation cascade to achieve hemostasis. Hematoma and clot formation ensue, which
are vital for a subsequently successful healing response
(283-288). Platelets contained within the clot release
a multitude of cytokines and growth factors, which
promote vascular dilation and permeability, resulting
in local edema and the recruitment of inflammatory
mediators. Neutrophils and monocytes infiltrate the region, where they digest and remove necrotic tissue and
debris, while also signaling for the infiltration of fibroblasts (251,283,285). Fibroblasts, along with numerous
growth factors, direct the transition from inflammation
to proliferation (251). Key features of proliferation
include collagen deposition, new ECM production, and
angiogenesis in an attempt to bridge the ends of a torn
ligament. Type III collagen is the predominant collagen
early in the healing process (251,285). Proliferation ultimately gives way to remodeling. During this stage, the
ECM is strengthened and further organized, with a shift
from type III to type I collagen (251,285).
In the vast majority of knee cruciate ligaments,
vascular channels at the ligament entheses form direct
contact between the ligament and the underlying bone
marrow (289). In addition, many entheses have a blood
vessel that enters the bone situated underneath the
part of attachment site that moves the least during
joint motion. Ligament health and the status of the
bone it inserts on are interrelated. For example, in one
study showing bone cysts at ACL insertion sites, 82%
demonstrated ligament pathology (290). Hence structurally this connection demonstrates that the ligament
has a relationship with the bone onto which it inserts.
MSCs possess the ability to migrate to sites of injury, and do so under the direction of a multitude of
growth factors, cytokines, and chemokines known to
be prevalent in the natural healing process of ligaments
(212,285,291,292). Additionally, there is evidence that
supports BM-MSCs as having a direct role in the natural
healing response following ligamentous injury. Much
of this evidence comes from dental literature investigating the response to injury of the PDL, a structure
that provides an attachment between the alveolar
bone and root surface cementum, and which is commonly injured during root canal treatments (280,293).
Multiple studies have analyzed the postinjury activity
at the PDL via mouse models, with green fluorescent
protein-labeled bone marrow (GFP+ BM) transplanted
into experimental mice via injection through the tail
vein (293-296). In each of these studies, GFP+ BM was
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observed to migrate to the PDL following injury (293296). In addition to demonstrating migration to the site
of injury, 3 of the studies also indicated differentiation
of the transplanted bone marrow into fibroblasts at
the PDL injury site, thus suggesting that BM-MSCs are
actively recruited to sites of ligamentous injury and differentiate into fibroblasts, thus being directly involved
in the natural healing process (293,294,296).
In a study by Kaku et al (280), GFP+ BM was transplanted directly into the femoral bone marrow of
recipient mice. Four weeks following transplantation,
teeth containing PDL were either extracted and immediately analyzed or immediately replanted, simulating
injury to the PDL in the replantation group (280). In
the extraction-only group, GFP+ BM-MSCs were detected within the PDL, predominantly with perivascular
localization near the bone surface of the PDL. In the
replantation group, following replantation, GFP+ BMMSCs were detected in larger quantities and dispersed
throughout the PDL. These findings suggest that bone
marrow plays a direct role in the natural PDL postinjury
response (280). Further, given that the GFP+ BM had
been transplanted into femoral bone marrow, and thus
located at a distance from the PDL, the study’s findings
suggest that these BM-MSCs are released into systemic
circulation to reach the target site (280).
Other studies focused on the ACL have also provided evidence of a direct role for bone marrow in ligamentous injury response. Morito et al (297) aspirated
synovial fluid from humans who had suffered ACL ruptures and found a significantly increased concentration
of MSCs in the synovial fluid as compared with noninjured controls. Although this study did not elucidate
the origin of the MSCs, it clearly indicated an increase in
response to the injury (297). A later study in ACL-injured
rat models indicated, via flow cytometry, a significant
increase in the MSC concentration in whole blood at
3 days postinjury in injured rats versus control group
(281). Though short of being confirmatory, the panel of
cell-surface receptors used were chosen based on their
ability to be used to identify BM-MSCs, and therefore
suggested that BM-MSCs are actively mobilized in a systemic fashion following injury to the ACL in rats (281).
In a second arm of this study, additional rats were intravenously injected with fluorescently labeled BM-MSCs
following ACL rupture (293). These labeled BM-MSCs
were observed to actively migrate to the injured joint,
providing further evidence that BM-MSCs migrate to
the location of acute ligamentous injury (281). The fact
that these BM-MSCs seemed to localize to the synovium
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and myotendinous junction, as opposed to the actual
ACL, may be explained by the ACL’s well-recognized
poor self-healing potential (283,286,287).
Clinical studies in which local bone marrow cells are
used to facilitate ligament healing are also important
as they demonstrate the simple surgical methods, such
as bone marrow stimulation, can release adjacent bone
marrow capable of healing the tear (282). For example,
Gobbi and Whyte (282) published a case series of athletes with partial ACL tears who were treated with a
local marrow stimulation procedure and who had excellent outcomes. Rodkey et al (298) also confirmed this
local healing marrow-based ligament response with experimentally created PCL injuries in dogs. These studies
clearly indicate that if a natural fracture were to occur
simultaneously with the knee ligament injury, causing
bone marrow to leak onto the damaged ligament, that
the natural ligament healing response would be augmented (282,298). Centeno et al (286,288) also demonstrated improvements in pain and functional outcomes
out to 3 years following percutaneous, fluoroscopically
guided BMC injection into the ACL for treatment of
grade 1, 2, and 3 tears with minimal retraction in a 2
case series.
In conclusion, the natural healing response following ligamentous injury is like that of other tissues, with
phases of inflammation, proliferation, and remodeling.
Multiple cells and signaling molecules are involved in
the process. Currently, available evidence suggests BMMSCs play an active role in this process, likely through
increased migration via systemic circulation to the site
of ligamentous injury.

Tendon
There is a clear relationship between the tendon
and the bone on which it inserts. Tendon healing involves both intrinsic and extrinsic cellular factors (299).
In addition, the health of the tendon has been tied to
the underlying number of MSCs in the bone marrow
of the insertion (300). Surgeons have taken advantage
of this association by using natural local bone marrow
cells, as well as BMC injections to improve the quality of
surgical tendon repairs (301).
Tendons have poor blood supply in certain regions
and can be notoriously difficult to heal (302). Normal
tendon healing involves both intrinsic and extrinsic cellular mechanisms. These include local tendon-derived
MSCs and progenitor cells, as well as cells recruited to
the site of injury from the surrounding periphery (287).
In a labelled bone marrow MSC mouse model, Kaji-
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kawa et al (303) demonstrated that bone marrow MSCs
entered the peripheral circulation and were recruited
to the injured tendon at various times in the healing
process. These worked synergistically with local tendonderived MSCs to repair the tendon injury (303). Tendon
healing follows 3 main phases that occur with overlap
and variations in duration (299). During the inflammatory stage, monocytes, neutrophils, and macrophages
travel to the injury site. Several days later, the proliferation stage involves the synthesis of type III collagen in
the ECM and activation of local progenitor cells, followed last by the remodeling stage during which type I
collagen predominates to restore the tendon strength,
orchestrated through a cascade of local growth factors
(299).
The relationship between the tendon and its underlying bone do appear linked, similarly to the interrelation between cartilage and bone. Hernigou et al
(304) found reduced levels of MSCs at the tendon-bone
interface in patients with symptomatic rotator cuff
tear. Considering this association, surgeons have used
this natural relationship between tendon and bone by
using marrow stimulation (304). In this technique, the
surgeon drills holes in the bone at the tendon insertion
to release natural bone marrow cells into the repair site
to augment the healing process (305-307). Effectively,
this allows direct access of these cells to the damaged
tendon rather than the cells mobilizing to the peripheral circulation and then to the area being repaired,
which would only occur if a blood supply existed in this
poorly vascularized injury region.
In addition to creating channels from the bone
marrow to the tendon to enhance the healing process,
BMC taken from other areas can also enhance tendon
healing (133,304). It has been demonstrated that injecting BMC into surgical rotator cuff tendon repairs
halves the retear rate of those tendons (133). This is also
supported by animal models, which demonstrate that
higher failure to load and enhanced tendon-to-bone
healing is observed in tendons treated with BMC and
surgical repair (308). Finally, partially torn rotator cuff
tendons injected with BMC showed improved pain and
function versus those treated by physical therapy alone
(309).

Muscle
Muscle has several self-repair mechanisms, both
intrinsic and extrinsic. This includes local satellite cells
and cells recruited from other areas, including the bone
marrow (251). One rationale for supplementing muscle
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repair is that it is often imperfect, with many animal
models demonstrating bone marrow MSCs can assist in
the repair process (310).
Like other musculoskeletal tissues, skeletal muscle
follows 3 phases of muscle tissue repair: the initial
inflammatory phase, followed by a repair phase, and
finally a remodeling phase (311,312). The inflammatory
phase starts with the initial muscle rupture, hematoma
formation, and muscle necrosis, which triggers the
complement cascade and recruitment of neutrophils
and macrophages to the site of injury. These cells
phagocytose and digest the damaged tissue and cellular debris while releasing cytokines (tumor necrosis
factor (TNF)- alpha, IL-1, IL-6 and IL-8, as well as IGF-1)
that recruit additional inflammatory mediators and
also signal resident satellite cells to proliferate (313).
In the repair phase, M2 macrophages promote satellite cell differentiation into new myoblasts (312). These
myoblasts will subsequently bind to one another or to
existing myofibrils to fill the muscle defect. At the same
time, MSCs will communicate via paracrine signaling
with the surrounding environment, recruiting fibroblasts, which will attempt to bridge the defect with
dense scar, and prompting new blood vessel and nerve
growth, via the secretion of numerous growth factors
(IGF-1, hepatocyte growth factor, FGF, VEGF-A, brain
derived neurotrophic factor, etc.) and immunomodulatory cytokines, which ultimately provides the building
blocks for muscle regeneration (314-316). The last
phase in muscle injury is the remodeling phase characterized by reorganization of both scar and myofibers
to ultimately optimize efficient force production. It has
been shown that MMPs can digest fibrotic scar tissue
and signal an influx of new progenitor cells, capable
of further differentiation into new myofibers (313,317).
Muscle fibers do not multiply, rather they are repaired and maintained by many neighboring cell types
throughout adult life (318). It has been demonstrated
that satellite cells, which lie adjacent to muscle fibers
along the basement membrane are mitotically active,
capable of self-renewal, and possess the ability to differentiate into myonuclei, which replace the damaged
muscle fibers (319). Satellite cells were traditionally
thought to be the primary myogenic stem cell equivalent, responsible for muscle regeneration and maintained entirely by self-renewal, however, this has been
called into question as others have found that several
other neighboring progenitor cells, such as endothelialassociated cells, interstitial cells, and BM-MSCs, also
function to maintain and replete the satellite cell pool
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(319). In response to skeletal muscle injury, BM-MSCs
react by mobilizing through the peripheral circulation, ultimately differentiating into both functioning
satellite cells and new myofibers (320,321). Thus the
relationship of bone marrow progenitor cells and their
importance in supporting the muscle satellite cell pool
is thought to be crucial to normal muscle tissue repair.
The muscle repair process is often imperfect in
the injury model. New muscle fibers have been found
to have various structural abnormalities, can deposit
themselves outside of the basal lamina, and can form
aberrant attachments to the surrounding scar tissue,
all of which can result in functional impairment of the
new muscle tissue (322). Thus emerging concepts in the
treatment of muscle injury focus on augmentation of
the natural inflammatory and repair mechanism discussed earlier, with BM-MSCs to the site of injury. It is
well documented in the cardiac literature that autologous transplanted bone marrow cells can be used to regenerate portions of infarcted myocardium (323-326).
In a rat crush injury model, local injection of BM-MSCs
to injured muscle was shown to increase postinjury
muscle contractile force when compared with injection
with saline (327). Winkler et al (328) demonstrated a
dose-response relationship to the administration of
BM-MSCs, which resulted in greater maximum twitch
strength and tetanic contraction force. It was shown
by Natsu et al (329) that implantation of BM-MSC into
rat tibialis anterior muscles following laceration injury
promoted myofiber maturation and return to baseline
contractile force.
It is clear that the muscle repair mechanism is
similar to that of tendon, cartilage, and bone with
phases of inflammation, repair, and remodeling, which
function to restore myofiber structure and function to
best produce efficient force production. There is ample
evidence suggesting that BM-MSCs function is not only
to replace depleted muscle satellite cells, but is also
to differentiate into new myofibers in vivo. They also
possess the capability to both migrate to nearby sites
of injury, as well as distant injuries via the circulation.
As such, there is increasing interest in regenerative
musculoskeletal treatment strategies that augment this
natural muscle repair mechanism through additional
supplementation of BM-MSCs into an area of muscle
injury.

The Spinal Joint Complex and Disc
Spinal pain is the most common condition of all
chronic pain conditions. Based on the available evi-
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dence, lumbar intervertebral discs, facet joints, sacroiliac joints, ligaments, fascia, muscles, the nerve root and
its dorsal root ganglion, and the dural sleeve have all
been shown to be capable of transmitting pain in the
spine with resulting symptoms of spinal pain, chest wall
pain, and extremity pain (1-9,12,138,151-154). Spinal
pain is a complex and multifactorial entity, encompassing mechanical, physiological, and psychosocial dimensions. Genetic predisposition and environmental factors
including smoking, obesity, and abnormal mechanical
loading have been implicated in the pathogenesis of
low back pain (1-5,12). Based on the theory of the structural basis of spinal pain, coupled with advances in imaging and increased understanding of the mechanisms
of pain, there is increasing evidence that a significant
proportion of low back pain is associated with degenerative disease of the spine involving spinal joints and
the disc. Studies have shown that osteoarthritis of the
spine with involvement of facet joints and degenerative disc disease provide direct mechanistic association
with spinal pain due to nociceptive nerve in growth occurring in the painful degenerative intervertebral discs,
as well as into osteoarthritis of the arthritic facet joints
and sacroiliac joints (138).
Apart from the sacroiliac joint, which is a true synovial joint, the spine consists of a 3-joint complex (the articular triad), which is the basic anatomic and functional
unit of the spine, consisting of the intervertebral disc
and 2 symmetrical facet joints, which connect the adjacent vertebrae (3,4,138,330-348). Many biomechanical
studies have demonstrated that the intervertebral disc
and the 2 adjacent facet joints carry loads together in
the normal lumbar spine (335). Multiple studies have
demonstrated that the intervertebral disc is the initial
site of spinal degeneration and that the adjacent facet
joint degenerates as a result of disc degeneration (337339,347). However, other studies have indicated that
disc degeneration does not necessarily precede facet
degeneration (340-343). Consequently, it is quite likely
that the intervertebral disc and facet joints contribute
as a unit to the degenerative process (341,344,345). Lv
et al (346) concluded that there was a significant correlation between endplate defects, Modic magnetic resonance imaging (MRI) signal changes, disc degeneration,
facet tropism, facet orientation, and low back pain.
Although facet joints are true synovial joints, intervertebral discs are composed of an annulus fibrosus,
nucleus pulposus, and cartilaginous endplates (349).
During the process of degeneration, discs undergo morphologic changes with tears and dehydration. They also
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undergo changes in the molecular composition of their
structure such as apoptosis, accumulation of debris with
decreased diffusion of waste products, and decreased
proteoglycan synthesis (349). The molecular changes
are components of disc degeneration, which can lead
to spinal stenosis, radiculopathy, myelopathy, and mechanical low back pain. Facet joint arthritis is a clinical
and pathological process that involves the functional
degeneration of the synovial facet joints. Even though
it is viewed as a disease of articular cartilage loss and
bony hypertrophy, the process of degeneration actually involves the whole joint, including the subchondral
bone, cartilage, ligaments, capsule, synovium, and
periarticular paraspinal muscles and soft tissues (347).
As described earlier, in the 3-joint complex, the intervertebral disc and the facet joints degenerate together.
Degenerative vertebral endplate and subchondral
bone marrow changes were first noted on MRI by
de Roos et al (350) in 1987. These MRI changes were
formally classified in 1988 by Modic et al (351). Type
1 Modic change is defined as a hypointense signal of
the vertebral endplate and body on the T1 images
and hyperintense on T2 images, especially on the STIR
sequence. This signal change represents bone marrow
edema and inflammation and is associated with disruption and fissuring of endplates and the formation of
fibrovascular granulation tissue. These changes reflect
the inflammatory stage of disc degeneration. Type 2
Modic change is defined as a hyperintense signal of the
vertebral endplate and body on the T1 images and hyperintense on nonfat suppressed T2 images. This is a result of the conversion of normal red hemopoietic bone
marrow into yellow fatty marrow as a result of marrow
ischemia. Modic type 3 changes are hypointense on
both T1 and T2 secondary to subchondral bone sclerosis.
Modic 1 and 2 changes are much more prevalent than
Modic 3, and these changes are most commonly seen
at the L4, L5, and S1 levels next to degenerated discs.
Modic changes are uncommon in asymptomatic individuals without degenerative disc disease (352). Kokkonen et al (353) have shown that, based on MRI and
computed tomography discography, there is a strong
correlation between vertebral endplate changes and
disc degeneration (346). The edema producing Modic
1 signal changes are secondary to microfractures of the
endplates and contiguous cancellous bone. There is an
increase in vascular density, in the number of nerve
endings due to nociceptive ingrowth, and in the levels
of proinflammatory chemical mediators, with these
vascular and inflammatory changes following the initial
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mechanical phenomena (352). Ohtori et al (354) found
that inflammatory cytokines and nerve ingrowth into
vertebral endplates may be a cause of discogenic low
back pain and that Modic type 1 changes, representing
more active inflammation, seem to be mediated by proinflammatory cytokines, whereas type 2 and 3 changes
are more quiescent stages of the process. Kjaer et al
(355) has demonstrated that degenerative disc disease
by itself is a fairly benign condition, whereas degenerative disc disease with Modic changes is much more
frequently associated with clinical symptoms. Among
Modic changes, type 1 changes are the ones most
strongly associated with low back pain (352). Mitra et al
(356) has found that type 1 Modic changes are dynamic
lesions that, in most cases, either increase in size or convert into type 2 changes. They have also demonstrated
that the evolution of type 1 Modic changes into type
2 changes result in the improvement of symptoms. In
addition, they observed that patients in whom type 1
changes increased were clinically worse. Finally, various
types of Modic changes can coexist with each other in
the same vertebrae (330).

BMC in the Spine
The intervertebral disc and the bone marrow located in the vertebral body are in constant communication
in the same way that cartilage and subchondral marrow
in all joints (including the facet joints) make up one biologic unit. The spine also contains ligaments and muscles,
and the earlier described principles of homology would
apply to those structures as well, meaning that bone
marrow is homologous to the functional spinal unit.
The vertebral bone marrow and the intervertebral
disc are in constant communication to maintain the
health of that structure. For example, Dudli et al (332)
found that in intervertebral discs with Modic changes,
fibrogenic and pro-inflammatory cross talk between
the vertebral bone marrow and adjacent disc is a critical
part of the disease process. In addition, other authors
have found that the degenerative processes in the disc,
endplate, and bone marrow are highly associated (334).
In a recent MRI diffusion study, the lack of bone marrow perfusion across the endplate was associated with
degeneration of the intervertebral disc (336). Hence
the status of the bone marrow in the vertebral body
impacts the health of the disc, meaning that the vertebral bone marrow and the intervertebral disc are one
homologous biologic unit.
Increases in the level of high-sensitivity C-reactive
protein in patients with low back pain and Modic type
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1 changes indicate local inflammation in vertebral endplates. The same is not shown for Modic type 2 and type
3 changes. However, it is now clear that subchondral
bone sclerosis and endplate fissuring is present in all
types of Modic changes. The different Modic types
are believed to represent different stages of the same
pathological process. Modic changes can convert from
one type to another, most commonly from type 1 to
type 2. Type 1 can also be reversed to normal only if the
underlying mechanical and molecular abnormalities are
resolved, which is very rare. Modic type 2 is more stable.
Rarely, type 2 will convert to type 3. There is evidence
to suggest that patients with an increased tendency
to inflammation and changes in bone marrow at the
vertebral endplates also have an increased tendency to
develop long-term back pain (357).
The endplate is the primary pathway for transport
between vertebral capillaries and the many cells within
the annulus and the sparse cells within the disc nucleus.
Blood vessels and marrow spaces abut the cartilaginous
and cortical bone layer of the endplate, providing channels for glucose and oxygen to enter the disc and for
waste products to exit the disc.
BMC therapies in intervertebral disc degeneration
repopulate the intervertebral disc and restore functional tissue through matrix synthesis by implanted
cells and potentially beneficial influences on native
cells (3,79,80,82-87,98,105-107,349). Stem cells serve
as a source to replace the nonviable cells of the annulus fibrosus and nucleus pulposus (349). Autologous
nucleus pulposus cell reimplantation has been shown to
retard degenerative changes in a dog model (358,359);
however, as the nucleus pulposus is relatively hypocellular, harvesting sufficient cells for reimplantation may
result in injury to the disc. Further, nucleus pulposus
cells from degenerated discs display, premature senescence and a catabolic metabolism (334,337,359-361),
which make them unsuitable for transplantation in
which normal cell function is required. Thus MSCs have
been proposed as an ideal cell source of regeneration.
An increasing number of studies have demonstrated
the ability of BM-MSCs to differentiate into nucleus
pulposus-like phenotype (discogenic differentiation).
The literature has shown that BM-MSCs can differentiate into osteoblasts, adipocytes, chondroblasts, and
cells having the phenotypic features of the intervertebral disc under proper in vitro conditions (362-364).
Further, the capability of BM-MSCs to differentiate into
nucleus pulposus-like cells and their ability to stimulate
production of a new cell matrix has been described
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(365). This hypothesis was tested by Mochida et al (366)
for intervertebral disc repair with activated nucleus
pulposus cell transplantation over a 3-year prospective
clinical study of its safety. Multiple other investigators
also have studied the results of implantation of MSCs
(87,366-371).
In vivo studies have also demonstrated the ability of implanted MSCs to enhance matrix production,
particularly glycosaminoglycan synthesis, resulting in
increased disc height and hydration (372-377). Early
studies on discogenic differentiation of MSCs relied on
the fact that nucleus pulposus cells are chondrocyte-like
and express chondrogenic markers, such as SOX-9, type
II collagen, and aggrecan (378). In preclinical studies of
the use of stem cells in the spine (379-381), adult stem
cells derived from bone marrow showed promise for
both osteogenesis and chondrogenesis. Further, various
growth factors and scaffolds have also been shown to
enhance the properties and eventual clinical potential
of these cells.
The descriptions of immunomodulation of MSCs in
discogenic pain by Miguélez-Rivera et al (382) showed
that conditioned media from MSCs downregulated
the expression of various proinflammatory cytokines
produced in the pathogenesis of discogenic pain, such
as IL-1, IL-6, IL-17, and TNF. Discogenic cells generated
from different adult human donors were also evaluated
for surface marker expression profile, matrix deposition, and tumorigenic potential (383). Subcutaneous
injection of discogenic cells into nude mice to assess
cell survival and possible ECM production in vivo, and
assessment of therapeutic potential of discogenic cells
after disc injury in a rabbit model of disc degeneration
showed that discogenic cells have a consistent surface
marker profile, are multipotent for mesenchymal
lineages, and produce ECM consisting of aggrecan,
collagen 1, and collagen 2 (383). This study concluded
that intradiscal injection of discogenic cells may be a
viable treatment for human degenerative disc disease
with production of ECM that may rebuild the depleting
tissue within the degenerated discs without any significant safety concerns.
The role of MSCs in healing and regeneration
by studying autologous BMC MSC migration into the
injured intervertebral disc has been investigated (384389). MSC homing has been reported to play a role in
the endogenous regeneration of different skeletal tissues, including bone and cartilage. In vivo, this process
is tightly controlled by a gradient of signalling molecules. In the intervertebral disc, recruitment of bone
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marrow cells toward the regenerating intervertebral
disc has been demonstrated in a mouse tail model in
vivo. However, the findings from the intervertebral disc
degeneration model suggests that the pool of available
cells or their recruitment efficiency may need to be enhanced by exogenous means to achieve a significant regenerative effect (384). Thus, migration of exogenously
delivered BM-MSCs through the endplate into the
intervertebral disc has been described as an alternative
approach for intradiscal cell treatment in several whole
intradiscal organ culture models (388-391). Wangler
et al (384) in an experimental study with human MSC
and intervertebral disc tissue samples showed that MSC
homing was involved directly in the maintenance of the
human intervertebral disc (392).
Wang et al (83), in a systematic review and metaanalysis of controlled trials using animals to investigate
the efficacy of intervertebral disc regeneration with
stem cells, demonstrated that stem cells transplanted
into the intervertebral discs of quadripedal animals decelerate or arrest the intervertebral disc degenerative
process. In another systematic review of comparative
controlled studies regarding the potential benefits of
using MSCs in disc degeneration, Yim et al (393) showed
that bone marrow MSCs produced a significant inhibition of disc degeneration with a better quality of repair
compared with non-MSC treatments.
Bone marrow MSCs that can be altered genetically
to express specific genes and differentiate into terminal
cells used in bone fusion are also currently being investigated for spine fusion. Comparisons are made to local
or harvest autografts (349,394). In vivo experiments
involve the injection of genetically engineered MSCs
that express recombinant human bone morphogenic
protein into sites for spinal fusion (395). BMC MSCs with
the ability to differentiate into adipocytes, osteoblasts,
and chondroblasts continue to proliferate, providing
an important source of bone formation to enhance
the spinal fusion (124,396). However, the therapeutic
potential of BMC MSCs is curtailed by the small number
of osteoprogenitor cells (397). Consequently, selective cell retention technology has been described as a
novel method to enrich the graft material with BMC
MSCs obtained with bone marrow aspiration through a
simple and effective method for intraoperative concentration of MSCs without the need for ex vivo expansion
that improves the characteristics of the graft material
(398,399). Further, a study of long-term radiologic and
clinical outcome after using bone marrow MSC concentrate obtained with selective retention cell technology
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in posterolateral spinal fusion showed a fusion rate of
100% (396). This is in contrast to nonunion rate of 25%
to 30% and pseudoarthrosis of 23% to 44% (400,401),
with the incidence of reoperation following lumbar
fusion surgery of 20.1% (402). Multiple other studies
have been published showing increased levels of fusion
(394).

Clinical Outcomes
BMC-MSCs are utilized in managing all types of
musculoskeletal conditions, including for spine regeneration and fusion.
A literature search was carried out utilizing multiple databases. The literature search involved bone
marrow stem cell research with key words of BMC and
BMC implant into various musculoskeletal and spine
structures. A total of 3,488 manuscripts were identified
through December 2019.

Spine
BMC is utilized for multiple types of interventions
in the spine, including intraarticular injections of facets and sacroiliac joints, disc injections, and epidural
injections.

Disc Injections
An overwhelming majority of the research with
BMC stem cells is focused on the lumbosacral spine.
Navani et al (3) published guidelines based on appropriate search criteria, study selection, methodologic
quality assessment, and analysis of evidence that included qualitative, as well as quantitative, analysis with
conventional dual arm and single arm meta-analysis.
Navani et al (3) identified 5 systematic reviews (79,8386). The overall majority of the studies used BM-MSCs,
concluding that BM-MSCs were the gold standard.
Khan et al (84) studied not only intervertebral disc
repair and spinal fusion, but also spinal cord injury. This
review identified almost 2,600 manuscripts; however,
only 53 met eligibility criteria. Of these, there were 28
studies on intervertebral disc repair and 9 studies on
spinal fusion. This systematic review concluded that
MSCs were a very good source for treatment of spinal
conditions.
Wu et al (86) reported the results of 6 studies with
a 44.2 point decrease in the pooled mean difference
in pain scores, and a 32.2 point pooled mean difference in the Oswestry Disability Index with no adverse
effects. In this systematic review, 3 studies used stem
cells (369,403,404) and 3 studies used chondrocytes
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(87,366,368). The mean follow-up time among the
6 trials was 22 months. In this analysis, they reported
that one study found improvements in the disc contour
or height posttreatment (368). Another study showed
increase in the fluid content of the discs at 12 months
(369).
Basso et al (85) in a systematic review identified
4 manuscripts (366,369,403,405) that involved the use
of stem cells. All of the studies reported that the intradiscal injection of stem cells was safe with variable
effectiveness.
Sanapati et al (79) in a systematic review of 26 manuscripts, included 7 studies utilizing stem cells (87,367404,406,407) with one study having 3 publications. The
results showed level III evidence for disc injections of
MSCs, and level IV evidence for epidural injections, lumbar facet joint injections, and sacroiliac joint injections,
with qualitative and quantitative synthesis of evidence
using conventional and single-arm meta-analysis. Appendix Table 1 shows the characteristics of the included
studies of stem cell therapy in disc degeneration as
stated in ASIPP guidelines that were derived from the
systematic review of Sanapati et al (79).
Sanapati et al (79) in a single-arm meta-analysis,
as shown in Fig. 6, showed changes in the pain scores
(87,354,368,369,371,406). The pooled mean difference in the decreased pain scores from baseline to the
12-month follow-up was 36.943 points (95% confidence
interval [CI]: -49.855 to -24.030, P < 0.001). Heterogeneity across the studies was high (I2 = 86%). They also
showed changes in the functional scores, as shown in
Fig. 7. Six studies reported on outcome assessment over
a period of 12 months (87,368,369,406,407). The pooled
mean difference in the decreased disability scores from
baseline to the 12-month follow-up was 26.342 points
(95% CI: -32.359 to -20.325, P < 0.001). Heterogeneity
across the studies was moderate (I2 = 55%).
Based on multiple systematic reviews (79,83-86),
as well as randomized and nonrandomized studies
included in systematic reviews and guideline development (3,87,354,366-407), there is level III evidence for
intradiscal injections of BMC.

Spinal Fusion
For a variety of spinal disorders, including trauma,
deformity, tumors, infection, instability, and degenerative spine disease, the rate of spinal fusion has been
increasing at an escalating pace (396). However, following fusion, repeat surgery was shown to be present
in approximately 20% of the patients (402), pseudoar-
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Fig. 6. Changes in pain score (Numerical Rating Scale or Visual Analog Scale, 0-100) after treatment (12 months follow-up
data) of cell therapy of lumbar disc.
Adapted from: Sanapati J, et al. Do regenerative medicine therapies provide long-term relief in chronic low back pain: A systematic review and
metaanalysis. Pain Physician 2018; 21:515-540 (79).

Fig. 7. Changes in Oswestry Disability Index after treatment (12 months follow-up data) of cell
therapy of lumbar disc.
Adapted from: Sanapati J, et al. Do regenerative medicine therapies provide long-term relief in chronic low back pain: A systematic review
and metaanalysis. Pain Physician 2018; 21:515-540 (79).

throsis after posterolateral lumbar fusion varying from
23% to 44% (400,401), and nonunion in 25% to 30%
depending on the procedure (394). Shah and Hsu (394)
reviewed all of the studies available using autologous
MSCs (n = 11) from bone marrow aspirate. Overall, the
studies have shown increased fusion rates as high as
100% (396,408-412).

Facet Joint Intraarticular Injections
Facet joints are true synovial joints and have been
proven to cause neck, upper extremity, mid back, upper
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back and chest wall, and low back and lower extremity
pain (138). The majority of the literature of biologics is
based on intraarticular injections in the lumbar spine of
platelet-rich plasma (PRP), which have been shown to
have positive results (79). Controlled diagnostic studies
have shown the prevalence of facet joint pain in 36%
to 67% in the cervical spine, 34% to 48% in the thoracic spine, and 27% to 41% in the lumbar spine based
on controlled comparative local anesthetic blocks in
patients without disc herniation or radiculitis (138,412416). Based on the results of PRP injections (79), the
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Table 5. Overall results of the comparisons of MSC injections for knee osteoarthritis with 72% of included studies injected BMC.

Outcome

Baseline

12 months

Estimated effect, IV, Random
(95% confidence interval)

Mean (SD)

Mean (SD)

0-12 Months

P

VAS score

55.28 (18.37)

20.08 (91.54)

36.91 (30.36 to 43.43)

< 0.0001

WOMAC

25.66 (15.10)

24.98 (14.39)

15.60 (10.10 to 21.10)

< 0.0001

Walking Distance

71.90 (28.41)

57.33 (270.31)

316.72 (-696.54 to 63.10)

0.10

Lequesne Scale

33.76 (19.72)

20.70 (19.07)

12.90 (-1.35 to 27.15)

0.08

Overall

41.07 (12.17)

65.13 (13.56)

18.94 (27.00 to 10.88)

< 0.0001

Symptoms

51.27 (15.21)

69.57 (14.99)

14.14 (21.35 to 6.93)

0.001

Pain

49.55 (14.51)

69.57 (14.99)

22.03 (29.39 to 14.67)

< 0.0001

Function

50.36 (18.90)

76.87 (16.02)

21.54 (28.84 to 14.24)

< 0.0001

Recreation

27.84 (17.46)

57.97 (21.17)

23.07 (32.10 to 14.04)

< 0.0001

Quality of Life

32.69 (23.40)

54.87 (17.07)

14.07 (38.98 to -10.84)

0.27

KOOS

VAS = Visual Analog Scale; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index; KOOS = Knee injury and Osteoarthritis
Outcome Score.
Adapted from: Migliorini F, Rath B, Colarossi G, et al. Improved outcomes after mesenchymal stem cells injections for knee osteoarthritis: Results
at 12-months follow-up: A systematic review of the literature. Arch Orthop Trauma Surg 2019 [Epub ahead of print] (109).

results with BMC are expected to be equivalent or superior to PRP injections.

Sacroiliac Joint
The sacroiliac joint is a true synovial joint and has
been proven to cause low back and lower extremity pain
(138,417). Diagnostic studies have shown the prevalence
of sacroiliac joint causing low back pain in approximately
10% to 25% of patients (138,417). Even though there is
extensive literature discussing the use and effectiveness
of biologicals in the management of peripheral joint
pain, similar to facet joints, there is no literature on sacroiliac joint injections with BMC. However, based on the
results of PRP injections (79), the results with BMC are
expected to be equivalent or superior to PRP injections,
which have been shown to have positive results.

Epidural Injections
Epidural injections are performed to treat various types of spinal and extremity pain secondary to
disc herniation, nerve root irritation, discogenic pain
with radiation into the extremity, spinal stenosis, and
the postsurgery syndrome (138,418-422). There is vast
literature regarding the effectiveness of various modalities in managing discogenic and nerve root pain
(138,418-422). The effects of epidural injections of PRP
have been studied; however, there are no studies showing the effects of epidural BMC.
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Knee
Multiple publications of systematic reviews, randomized controlled trials, and continuing research,
show that injections of BMC or isolated bone marrow and MSCs show promise as a safe and effective
treatment for multiple knee conditions (88,109111,134,239,421-433). A recent systematic review by
Migliorini et al (109), assessing the stem cell injections
for knee osteoarthritis identified 18 studies, comprising
1,069 treated knees. BMC-MSCs were administered in
72% of the included studies with a mean Visual Analog Scale score improvement from 18.37 to 30.98 and
36.91 at 6- and 12-month follow-up, respectively. The
evaluation also showed improvement in functional
scores with improvement in the Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC)
score from 25.66 to 25.23 and 15.6 at 6- and 12-month
follow-up, respectively. The mean walking distance
improved from 71.9 to 152.22 and 316.72 at 6- and
12-month follow-up, respectively. Multiple other scores
also improved significantly. The authors have concluded
that according to the current evidence BMC infiltration
for knee osteoarthritis can represent a feasible option,
leading to an overall remarkable improvement of all
clinical and functional outcomes. Further, they have
also shown that patients treated at earlier degeneration stages reported statistically significant better outcomes (134,229,232,233,239,423-433). Table 5 shows
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Table 6. Clinical outcomes of studies of osteoarthritis using MSCs, with 8 of 17 studies using BMC.

Author

No. of
Patients
(Study/
Control)

Age

Gender
(F/M)

BMI

FU*
(mo)

Wakitani et al (229),
2002

24 (12/12)

63

15/9

NS

16

HSS

81.3 vs. 79.2
No signiﬁcant difference

Davatchi et al (231),
2011

4

58

2/2

30.3

12

Pain VAS, walking time,
number of stairs

Pain, walking time, and number of
stairs to climb improved

Emadedin et al (232),
2012

6

55

6/0

31.6

12

Pain VAS, WOMAC,
walking distance

All outcomes improved

Wong et al (237),
2013

56 (28/28)

51

29/27

23.9
(median)

24

IKDC, Lysholm, Tegner

All outcomes improved
Better scores in the MSC group*

Orozco et al (234),
2013

12

49

6/6

NS

12

VAS, WOMAC, SF-36

All outcomes improved

Vega et al (239), 2015

30 (15/15)

57

19/11

NS

12

VAS, WOMAC,
Lequesne, SF-12

All outcomes improved
Better scores in the MSC group*

Gupta et al (435),
2016

60 (40/20)

56

45/15

27.8

12

VAS, ICOAP, WOMAC

No signiﬁcant differences in all groups

VAS, WOMAC

All outcomes improved
Better improvement in the MSC
group*
Much improvement in the high-dose
group

Lamo-Espinosa et al
(433), 2016

30 (20/10)

61

11/19

28.4

12

Clinical Outcome

Description

BMI = body mass index; HSS = hospital for specific surgery; ICOAP = intermittent and constant osteoarthritis pain; IKDC = International Knee
Documentation Committee; VAS = Visual Analog Scale score; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index; SF36 = Short Form-36; SF-12 = Short Form-12; MSC = mesenchymal stem cell; NS = not specified; F/U = follow-up.
Adapted from: Ha CW, Park YB, Kim SH, Lee HJ. Intra-articular mesenchymal stem cells in osteoarthritis of the knee: A systematic review of clinical outcomes and evidence of cartilage repair. Arthroscopy 2019; 35:277-288 (111).

the comparisons of outcomes after MSC injections for
knee osteoarthritis, published in the systematic review
by Migliorini et al (109).
There have been multiple other systematic reviews (88,110,111,134,434). Ha et al (111) performed
a systematic review assessing intraarticular MSCs for
the osteoarthritis of the knee along with evidence of
cartilage repair including a total of 17 studies, with
8 studies (229,232,233,237,239,424,425,433,435,436
) using bone marrow derived MSCs. They concluded
that intraarticular MSCs provided improvement in pain
and function in knee osteoarthritis with follow-up of
less than 28 months in many cases. They also showed
efficacy of MSCs for cartilage repair in osteoarthritis.
However, they concluded that evidence of efficacy of
intraarticular MSCs on both clinical outcomes and cartilage repair was limited to level III evidence. Table 6
shows the characteristics and clinical outcomes of the
studies of osteoarthritis using BMC.
Chahla et al (88) also performed a systematic review of outcomes of the concentrated bone marrow
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aspirate for the treatment of chondral injuries and
osteoarthritis of the knee. They identified 8 studies
evaluating the efficacy of BMAC on focal cartilage injuries (430-433,435-445), and 3 studies evaluating the
clinical efficacy of BMAC in the treatment of osteoarthritis (430,437,446). All 11 studies with patients having
osteoarthritis and chondral effects reported good to
excellent overall outcomes with the use of BMAC.
Cavinatto et al (434) in a systematic review and critical analysis in animal and clinical studies of assessing
the role of BMAC for the treatment of focal chondral
lesions of the knee reported the results of 13 clinical
studies. Overall, all clinical studies, independent of the
study group or level of evidence, reported improved
clinical outcomes and higher macroscopic, MRI, and histology scores. However, clinical studies were scant and
showed low scientific rigor, poor methodologic quality,
and low levels of evidence on average.
In a systematic review of human studies of officebased MSC therapy for the treatment of a variety of musculoskeletal disease, Law et al (110) identified 8 studies
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with a total of 941 patients (228,236,406,430,447-450).
Overall, they concluded that support in the literature is
strongest for the use of BMAC injections for the treatment of knee injuries.
Two recent randomized controlled trials have also
been published that use BMC injections to treat knee
osteoarthritis. Centeno et al (451) published a randomized cross-over trial of high-dose BMC injected versus
physical therapy showing excellent results compared
with control. Gobbi et al (470-471) published a smaller
group of patients who used low-dose BMC diluted with
high volumes of platelet poor plasma and observed
good results in both the osteoarthritis and saline control groups.
BMC injection using fluoroscopic guidance has also
been used to repair ACL injuries. Centeno et al (451)
have published 2 case series with imaging outcomes
showing evidence of healing both on MRI and with
functional questionnaires (453,454). In these cases,
similar to surgical results were obtained only through
precise injection.
In summary, BMC demonstrated beneficial effects
not only in knee osteoarthritis, but in the repair of ACL
and other injuries involving cartilage and cortical bone.
Based on the evidence derived from multiple
systematic reviews (88,109-111), relevant randomized
controlled trials (229,231,232,234,237,239,430,433,435
,437,446), and multiple observational studies, there is
moderate or level II evidence for treatment of knee osteoarthritis, there is level III evidence based on systematic reviews, randomized controlled trials, and observational studies of focal cartilage injuries (88,440,445).

Hip
BMC has been shown to produce reasonable outcomes for hip injections (108). Despite the emerging literature with overall hip injections, the literature related
to implantation of autologous bone marrow stem cells
compared with other modalities of treatments in osteonecrosis of the femoral head is significant (109,455). In
fact, Wang et al (455) in a meta-analysis of core decompression combined with autologous bone marrow stem
cells versus core decompression alone for patients with
osteonecrosis of the femoral head included 14 studies
with 540 patients (456-469). They included studies from
2004 to 2018. Further, studies were mainly published
in Belgium and China. Results of meta-analysis showed
the core decompression combined with bone marrow
stem cells was superior in pain reduction at 6 months,
12 months, and 24 months, and a decrease in number
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of hips undergoing total hip arthroplasty, the WOMAC
score, and the volume of the postoperative necrotic
zone. Among the multiple reports available, Centeno
et al (470) evaluated 196 patients with hip osteoarthritis treated with BMC percutaneous-guided injection.
Patients reported relief of pain and better function;
there were no severe or serious adverse events (470). In
2006, the same authors (471) had already demonstrated
a partial regeneration of a severely degenerated hip 8
weeks after bone marrow aspirate injection; the results
were confirmed by MRI. Chahla et al (472) described in
a review article the successful use of BMC for hip osteoarthritis in their institution, with good clinical results
and no adverse effects reported.
Regarding soft tissues injuries of the hip, there is a
lack of publications showing BMC use in humans. However, there are several reports of bone marrow use on
animals, some in other body parts, and a vast literature
about PRP (108). Due to biological similarities between
BMC and PRP, as well as the verified safety of the former, its use for this purpose must increase in the next
years. Torricelli et al (473) demonstrated impressive results using a combination of BMC and PRP to treat overuse injuries in competition horses, achieving an almost
85% rate of return to competition. Campbell et al (474)
treated a professional soccer player with capsular injury
and tear of the gluteus minimus tendon using both
BMC and PRP. They described improvement of pain and
strength, as well as the morphologic changes on MRI.
Recent studies of hip osteonecrosis have demonstrated that there is a decrease in the number and
function of mesenchymal cells in the trochanteric region and in the femoral head of patients resulting in a
limited healing capacity of the necrotic areas (470,471).
Mononuclear cell transplantation appears to be a minimally invasive technique capable of reducing pain and
preventing the progression of these lesions (470-473).
Data show that after femoral head collapse, the
rate of treatment failure increases greatly. Other factors that may impair biological treatment would be the
use of corticosteroids and alcoholism (472-474).
The most common technique for grafting the
mononuclear cell concentrate into the hip is through
the decompression tunnels into the necrotic areas
of the femoral head. The concentrate can be applied
alone or in combination with a scaffold that guarantees
mechanical support and the presence of the cells in the
areas of necrosis (475-477). A few studies have used
transplantation of mononuclear cells by selective catheterization of the medial circumflex artery (450,478), or
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the intravenous injection of mesenchymal cells betting
on the ability of the cells to home in on injured tissues
(479).
The variation in the techniques of collection, concentration, and grafting shows the lack of uniformity of
the methods, which leads to the difficulty of comparing
the data in the literature.

Ankle
The use of BMC for the treatment of osteochondral
defects and osteoarthritis of the talus was reviewed by
Chahla et al (480). In this systematic review, 4 studies
that used BMC to augment a variety of surgical techniques for the treatment of osteochondral lesions of
the talus were analyzed.
Clinical improvement in Orthopaedic Foot and
Ankle Society (AOFAS) score and MRI scan were observed in 48 patients with posttraumatic type II lesion
of the talar dome. These patients underwent a one-step
arthroscopic technique for cartilage repair and treated
with BMC and collagen powder or hyaluronic acid
membrane as scaffolds for cells and platelet gel (481).
The studies also showed that at 24 months follow-up
new tissue was formed. The clinical outcomes were
maintained in these patients for 4 years after treatment, although there was a decline in the AOFAS scores
between 24 and 48 months of follow-up (482).
Outcome measures were reported in Foot and
Ankle Outcome Score and in Short Form-12 general
health questionnaire in patients with lesions of the
talus after autologous osteochondral transplantation
with BMC (483).
Retrospective outcomes after osteochondral lesions of the talus treated with arthroscopy followed by
talar bone marrow stimulation with and without BMC
as a biological adjunct were analyzed in 22 patients
(484). The results show that the use of BMC resulted
in similar functional outcomes, but improved border
repair tissue integration, with less evidence of fissuring
and fibrillation on MRI.
The use of BMC for acute sports-related Achilles
tendon rupture was demonstrated in studies with 27
patients (485). In this group of patients, there were no
adverse outcomes or reruptures.

Shoulder
Poor microcirculation of the human rotator cuff
results in chronic lesions that do not heal and tend to
increase in size over time, increasing the number of
symptomatic patients (108,486,487).
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Several experimental studies on the use of mesenchymal cells for the treatment of tendinopathies have
shown encouraging results. The healing of the surgical
repair occurs with the formation of fibro-cicatricial tissue
of low quality. The use of BMC in the treatment of the
rotator cuff aims to improve the quality of tendons and
their healing (108). The BMC can be applied at the lesion
site by direct injection or associated with scaffolds.
In a clinical study (488) of rotator cuff repair using
the mini-open technique with transosseous suture and
application of bone marrow mononuclear cells, a full
tendon reconstruction was observed in patients at 12
months follow-up. In this study, the improvement of
University of California at Los Angeles score (31 ± 3.2) in
13 of 14 patients remained unchanged up to the second
year follow-up.
The BMC outcomes were demonstrated in a group
of 90 patients undergoing arthroscopic repair of the supraspinatus tendon (133). Half of the patients received
BMC injection at the tenodesis site and half were included in the control group (without BMC treatment).
After 6 months of follow-up, the BMC group had 100%
repair healing versus 67% in the control group. After
10 years of follow-up, 87% of the cases in the BMC
group still had intact tendon against 44% in the control group. Those patients in the treated group without
intact tendons had received the lowest number of applied MSCs. Centeno et al (489) published a midterm
analysis of a randomized crossover trial comparing percutaneous BMC with platelet-product injection versus
exercise alone treatment of partial or full nonretracted
supraspinatus tears. Outcomes of the 25 patients who
had reached 1 year follow-up showed significant improvements in pain at 3 and 6 months, and functional
improvements at 3 months with the majority of posttreatment MRI scan demonstrated decrease in tear size.
No adverse outcomes were reported (489).
A prospective study (490) was performed in patients with glenohumeral osteoarthrosis and in patients
with lesions of less than 1.5 cm of the rotator cuff. Both
groups were treated with an injection of BMC plus PRP
guided by ultrasound or radioscopy. BMC/PRP treatment led to significant improvement in the Disability of
the Arm, Shoulder, and Hand score, and in the numeric
scale of pain with subjective improvement in 48.8% of
the patients. There was no influence of age, gender,
body mass index, or BMC cell count on the result.

Position Statements
The position statements here are based on the
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survey of all the literature available, evidence synthesis
based on randomized controlled trials, observational
studies obtained from systematic reviews, guidelines,
and finally an academic Delphi investigation performed
on use of BMC to treat pain and musculoskeletal disorders (3,49,50,78-112,491).

STATEMENT 1
Based on a review of the literature in discussing
the preparation of BMC using accepted methodologies,
there is strong evidence of minimal manipulation in its
preparation, and moderate evidence for homologous
utility for various musculoskeletal and spinal conditions
qualifies for the same surgical exemption.

STATEMENT 2
Assessment of clinical effectiveness based on extensive literature shows emerging evidence for multiple
musculoskeletal and spinal conditions.
•
The evidence is highest for knee osteoarthritis with
level II evidence based on relevant systematic reviews,
randomized controlled trials, and nonrandomized
studies. There is level III evidence for knee cartilage
conditions.
•
Based on the relevant systematic reviews, randomized trials, and nonrandomized studies, the evidence for disc injections is level III.
•
Based on the available literature without appropriate systematic reviews or randomized controlled
trials, the evidence for all other conditions is level
IV or limited for BMC injections.

ber 2016 with provisions to accelerate the development
and translation of promising new therapies into clinical evaluation and use. This bipartisan and bicameral
legislation increased funding for medical research for
combating the opioid epidemic and included measures
to streamline approval of new therapies for clinical trials. It also provided a new expedited biologics product
development program called RMAT. Multiple activities
have been enforced by regulatory agencies at the federal and state levels to combat overuse, misuse, fraud,
and abuse; however, with no specific standards established in delivery of BMC therapy.

STATEMENT 6
Development of cell-based therapies is rapidly proliferating in a number of disease areas, including musculoskeletal disorders and spine. With mixed results, these therapies
are greatly outpacing the evidence (79,88,110,111,351373). The reckless publicity with unsubstantiated claims
of beneficial outcomes having putative potential has led
the FDA FTC to issue multiple warnings. Thus the US FDA is
considering the appropriateness of using various therapies,
including BMC, for homologous use.

STATEMENT 7
Since the 1980’s and the description of mesenchymal stem cells by Caplan et al (120), (now called medicinal signaling cells [MSCs]), the use of BMC in musculoskeletal and spinal disorders has been increasing in the
management of pain and promoting tissue healing.

STATEMENT 8
STATEMENT 3
Based on an extensive review of the literature, there
is strong evidence for the safety of BMC when performed
by trained physicians with the appropriate precautions
under image guidance utilizing a sterile technique.

STATEMENT 4
Musculoskeletal disorders and spinal disorders with
related disability are common with extensive health
care expenditures, taking a human toll with expenditures in 2013 in the United States of $183 billion per
year for musculoskeletal disorders, including back and
neck pain. Even then, disability continues to escalate
despite advancements with a wide array of treatment
modalities.

STATEMENT 5
The 21st Century Cures Act was enacted in Decem-
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As part of the regulation of HCT/Ps, including both
autologous and allogenic bone marrow-derived tissue preparations, are regulation by the FDA using the
PHSA. If the biologic is minimally manipulated and falls
under the same surgical procedure exemption found
at 21 CFR 1271.15(b), the biologic is exempt from FDA
regulation. BMC falls into this same surgical procedure
exemption jurisdiction from a minimal manipulation
standpoint, but only as long as it is also in treatments
that constitute homologous use.

STATEMENT 9
If the FDA does not accept BMC as homologous,
then it will require an IND classification with FDA (351)
cellular drug approval for use.

STATEMENT 10
This literature review and these position state-

www.painphysicianjournal.com

BMC Therapy in Musculoskeletal Disorders: Position Statement of ASIPP

ments establish compliance with the FDA’s intent and
corroborates its present description of BMC as homologous with same surgical exemption, and exempt from
IND, for use of BMC for treatment of musculoskeletal
tissues, such as cartilage, bones, ligaments, muscles,
tendons, and spinal discs.

Conclusions
Based on the review of all available and relevant
literature, position statements have been developed
showing the impact of musculoskeletal and spine disorders on health care costs, the opioid epidemic, and disability; evidence of minimal manipulation and homologous use based on MSCs and growth factors of BMC for
multiple musculoskeletal structures including the disc;
effectiveness and safety; and finally the evidence to
show that BMC in musculoskeletal disorders meets the
criteria of minimal manipulation and homologous use.
Consequently, using the FDA’s tiered, risk-based
approach to the regulation of HCT/Ps, BMC is minimally
manipulated within the same surgical procedure exemption, and meets criteria of homologous use. We hope
that this review is helpful to regulators as they seek to
regulate regenerative musculoskeletal medicine.

Disclaimer
These position statements are based on the best
available evidence and do not constitute inflexible
treatment recommendations. Because of the changing body of evidence, this document is not intended
to be a “standard of care.” These position statements
are meant to provide a basis for the understanding behind the role of BMC in the healing of musculoskeletal
disorders, including the spine, to provide a source of
appropriate indications for the use of BMC, to facilitate
and to help standardize BMC. These statements are also
to facilitate the FDA to continue to approve without
IND classification for BMC in musculoskeletal and spinal disorders. Finally, these statements are expected to
encourage the performance of high-quality studies in
an effort to document outcomes, and adverse consequences, to advance BMC applications, and to encourage high-quality training and competency assessment,
and the performance of high-quality studies in an effort to document outcomes, adverse consequences to
advance BMC applications.
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